BTIG lowered the firm's price target on Verastem to $18 from $19 and keeps a Buy rating on the shares after its Q1 results. The revamped commercial efforts should get the company back on track with long-term peak sales potential in LGSOC - Low-Grade Serous Ovarian Cancer - remaining intact, the analyst tells investors in a research note.
